Literature DB >> 30675477

Successful Total Resection of an Orbital Epithelioid Hemangioendothelioma with the Aid of Endovascular Embolization.

Mansooreh Jamshidian-Tehrani1, Bahram Eshraghi1, Mohammad Zarei1, Zohreh Nozarian1, Seyed Mohsen Rafizadeh1, Hadi Ghadimi1.   

Abstract

Hemangioendothelioma is rarely encountered in the orbit. We present a patient with a growing orbital mass for whom surgical excision was planned. Two previous attempts at removing the mass failed due to profuse bleeding. Endovascular embolization was performed before surgery to prevent massive hemorrhage. After embolization, retinal vascular accident (combined central retinal artery and vein occlusion) occurred. However, surgical excision (lateral orbitotomy and transcoronal craniotomy) was successful, and the vision improved postoperatively. Histopathologic examination and immunohistochemistry study confirmed the diagnosis of epithelioid hemangioendothelioma. The combined approach by a team of specialists, including an interventional radiologist performing preoperative embolization of the feeding vessel and joint surgery by a neurosurgeon and oculoplastic surgeon, was the key to the effective treatment of this vascular orbital neoplasm.

Entities:  

Keywords:  Endovascular intervention; Hemangioendothelioma; Orbital neoplasm; Retinal vascular occlusion; Vascular lesion

Year:  2018        PMID: 30675477      PMCID: PMC6341328          DOI: 10.1159/000489126

Source DB:  PubMed          Journal:  Ocul Oncol Pathol        ISSN: 2296-4657


  2 in total

1.  Preoperative transarterial embolization of a recurrent orbital solitary fibrous tumor with significant hypervascularity: a case report.

Authors:  Xiawei Wang; Jianqin Shen; Hongguang Cui; Jianwei Pan; Xiaodong Teng; Min Yan; Shi Feng; Wei Ding
Journal:  BMC Surg       Date:  2021-02-18       Impact factor: 2.102

Review 2.  Malignant Vascular Tumors of the Head and Neck-Which Type of Therapy Works Best?

Authors:  Susanne Wiegand; Andreas Dietz; Gunnar Wichmann
Journal:  Cancers (Basel)       Date:  2021-12-09       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.